HRP20180874T4 - Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze - Google Patents

Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze Download PDF

Info

Publication number
HRP20180874T4
HRP20180874T4 HRP20180874TT HRP20180874T HRP20180874T4 HR P20180874 T4 HRP20180874 T4 HR P20180874T4 HR P20180874T T HRP20180874T T HR P20180874TT HR P20180874 T HRP20180874 T HR P20180874T HR P20180874 T4 HRP20180874 T4 HR P20180874T4
Authority
HR
Croatia
Prior art keywords
formula
compound
use according
methods
enrichment
Prior art date
Application number
HRP20180874TT
Other languages
English (en)
Croatian (hr)
Inventor
Esther Martinborough
Marcus F. Boehm
Adam Richard Yeager
Junko Tamiya
Liming Huang
Enugurthi Brahmachary
Manisha Moorjani
Gregg Alan Timony
Jennifer L. Brooks
Robert Peach
Fiona Lorraine Scott
Michael Allen Hanson
Original Assignee
Receptos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180874(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Receptos Llc filed Critical Receptos Llc
Publication of HRP20180874T1 publication Critical patent/HRP20180874T1/hr
Publication of HRP20180874T4 publication Critical patent/HRP20180874T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20180874TT 2009-11-13 2010-11-15 Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze HRP20180874T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP10830880.0A EP2498610B2 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (2)

Publication Number Publication Date
HRP20180874T1 HRP20180874T1 (hr) 2018-07-13
HRP20180874T4 true HRP20180874T4 (hr) 2024-09-27

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20180874TT HRP20180874T4 (hr) 2009-11-13 2010-11-15 Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze
HRP20210446TT HRP20210446T1 (hr) 2009-11-13 2021-03-17 Selektivni modulatori receptora sfingozin 1 fosfata i postupci za kiralnu sintezu

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210446TT HRP20210446T1 (hr) 2009-11-13 2021-03-17 Selektivni modulatori receptora sfingozin 1 fosfata i postupci za kiralnu sintezu

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP3868377A1 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101752124B1 (enExample)
CN (2) CN102762100B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR122018077504B8 (enExample)
CA (2) CA2780772C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK3406142T3 (enExample)
EA (2) EA035768B1 (enExample)
ES (2) ES2673160T5 (enExample)
FI (1) FI2498610T4 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE037535T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT3406142T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY189750A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL3406142T3 (enExample)
PT (2) PT3406142T (enExample)
RS (2) RS57253B2 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI3406142T1 (enExample)
SM (2) SMT201800288T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2498611T (pt) 2009-11-13 2018-04-13 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral
CA2780772C (en) 2009-11-13 2018-01-16 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
SMT201700287T1 (it) * 2012-06-21 2017-07-18 Eisai R&D Man Co Ltd Nuovo derivato di indansolfammide
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
EP3062792A1 (en) * 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CA2981743A1 (en) 2015-04-06 2016-10-13 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
ES3022204T3 (en) 2016-06-14 2025-05-28 Receptos Llc Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
JP6883882B2 (ja) * 2016-07-22 2021-06-09 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｓ１ｐ１アゴニスト及びその応用
US11028060B2 (en) 2016-08-19 2021-06-08 Receptos Llc Crystalline forms of ozanimod and processes for preparation thereof
WO2018050091A1 (zh) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN108137516A (zh) * 2016-09-14 2018-06-08 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
JP7086945B2 (ja) 2016-09-29 2022-06-20 レセプトス・リミテッド・ライアビリティ・カンパニー 狼瘡を処置するための化合物および方法
JP7123956B2 (ja) * 2017-02-28 2022-08-23 ヘリオイースト・ファーマシューティカル・カンパニー・リミテッド スピロ化合物およびその使用
US20200031784A1 (en) * 2017-04-07 2020-01-30 Solipharma Llc Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
EP3621610A1 (en) 2017-05-08 2020-03-18 Celgene International II Sàrl Sphingosine 1 phosphate receptor agonists for neuroprotection
MA48798B1 (fr) * 2017-05-22 2023-10-31 Egyt Gyogyszervegyeszeti Gyar Procédé de production d'ozanimod
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10675255B2 (en) 2017-06-23 2020-06-09 Enzo Bochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
EP3677575A4 (en) 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
BR112020014488A2 (pt) * 2018-01-18 2020-12-01 Shijiazhuang Sagacity New Drug Development Company, Ltd. formas cristalinas e salinas do composto tricíclico e processo de preparação das mesmas
CA3092295A1 (en) 2018-03-20 2019-09-26 Eisai R&D Management Co., Ltd. Epilepsy treatment agent
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
CA3124986A1 (en) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
EP3849965A1 (en) 2018-09-12 2021-07-21 Pharmazell GmbH A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
MX2021006692A (es) * 2018-12-07 2021-07-07 Synthon Bv Proceso mejorado para preparar ozanimod.
CN113891883A (zh) * 2019-03-29 2022-01-04 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
EP3947362A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS
WO2020205483A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
US20220227722A1 (en) * 2019-04-26 2022-07-21 Receptos Llc Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
EP3999495A1 (en) 2019-07-16 2022-05-25 Synthon B.V. Improved process for preparing ozanimod
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
TW202135804A (zh) * 2020-01-06 2021-10-01 美商艾尼納製藥公司 治療與s1p1受體相關之病況的方法
EP4116295A4 (en) * 2020-03-04 2023-08-02 Helioeast Pharmaceutical Co., Ltd. TRICYCLIC COMPOUNDS AND THEIR USE
CN115279740B (zh) * 2020-03-04 2025-02-28 南昌弘益药业有限公司 苯并2-氮杂螺[4.4]壬烷类化合物及其应用
EP4121025A4 (en) * 2020-03-17 2024-03-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
JP2023518968A (ja) * 2020-03-27 2023-05-09 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１ホスフェート受容体モジュレーター
US12364686B2 (en) 2020-03-27 2025-07-22 Receptos Llc Sphingosine 1 phosphate receptor modulators
EP4126826A1 (en) 2020-04-02 2023-02-08 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
WO2022213935A1 (zh) * 2021-04-09 2022-10-13 南昌弘益药业有限公司 噁二唑取代的螺环类化合物及其应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
AU1886892A (en) 1991-04-12 1992-11-17 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA2318361A1 (en) * 1998-01-23 1999-07-29 Sankyo Company Limited Spiropiperidine derivatives
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
EP1581509B1 (en) 2002-12-20 2011-01-19 Merck Sharp & Dohme Corp. 1-(amino)indanes as edg receptor agonists
DK3549936T3 (da) 2003-04-11 2021-07-12 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
EP1670463A2 (en) 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
CA2600008A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
BRPI0614090A2 (pt) † 2005-08-03 2011-03-09 Novartis Ag uso de inibidores da hdac para o tratamento do mieloma
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
JP5514443B2 (ja) 2005-12-21 2014-06-04 ジョセフ ガブリエル， カテコールアミン調節性タンパク質
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP5250556B2 (ja) * 2006-09-21 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド フェニル誘導体及びそれらの免疫調節薬としての使用
WO2008064320A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008143730A2 (en) 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) † 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009131090A1 (ja) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
PL2291080T3 (pl) * 2008-05-14 2015-12-31 Scripps Research Inst Nowe modulatory receptorów sfingozyno-1-fosforanu
CN102066752B (zh) * 2008-06-13 2014-02-19 (学)斗源学院 具有回转阀的往复式压缩机
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
DK2498609T3 (en) 2009-11-13 2018-06-18 Celgene Int Ii Sarl SELECTIVE HETEROCYCLIC SPHINGOSIN-1 PHOSPHATRECEPTOR MODULATORS
CA2780772C (en) 2009-11-13 2018-01-16 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PT2498611T (pt) 2009-11-13 2018-04-13 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
KR101721716B1 (ko) 2017-04-10
IL219691A0 (en) 2012-07-31
CY2020035I1 (el) 2021-03-12
JP2015038145A (ja) 2015-02-26
HRP20180874T1 (hr) 2018-07-13
EP3868377A1 (en) 2021-08-25
AU2010319983B2 (en) 2015-03-12
EA035768B1 (ru) 2020-08-07
PL2498610T3 (pl) 2018-08-31
CA2986521C (en) 2020-06-30
US9388147B2 (en) 2016-07-12
EP2498610A1 (en) 2012-09-19
EP2498610A4 (en) 2013-05-22
NO2498610T3 (enExample) 2018-08-11
FR20C1059I1 (enExample) 2020-12-25
CY1124121T1 (el) 2022-05-27
PT3406142T (pt) 2021-03-26
TR201807912T4 (tr) 2018-06-21
WO2011060392A1 (en) 2011-05-19
JP5982705B2 (ja) 2016-08-31
MY189750A (en) 2022-03-02
HUS2000045I1 (hu) 2020-12-28
US20110172202A1 (en) 2011-07-14
HK1175948A1 (en) 2013-07-19
LTC2498610I2 (lt) 2022-06-10
FI2498610T4 (fi) 2024-08-29
EA201690391A1 (ru) 2016-08-31
BR122018077504B8 (pt) 2021-05-25
CY2020035I2 (el) 2021-03-12
DK2498610T3 (en) 2018-06-14
JP2014122208A (ja) 2014-07-03
PL3406142T3 (pl) 2021-08-30
HRP20210446T1 (hr) 2021-05-14
IL267956B (en) 2021-01-31
FR20C1059I2 (fr) 2021-12-10
CN102762100B (zh) 2015-07-01
MY161854A (en) 2017-05-15
HK1213874A1 (zh) 2016-07-15
BR122018077504B1 (pt) 2021-05-11
PH12015502708A1 (en) 2016-10-17
AU2010319983A2 (en) 2013-09-12
NZ599915A (en) 2014-07-25
SMT201800288T1 (it) 2018-07-17
BR112012011427B1 (pt) 2021-04-20
LUC00184I2 (enExample) 2024-07-01
RS57253B2 (sr) 2024-10-31
RS61829B1 (sr) 2021-06-30
KR20160149317A (ko) 2016-12-27
KR101752124B1 (ko) 2017-06-28
US20150299149A1 (en) 2015-10-22
AU2010319983A1 (en) 2012-05-31
DK3406142T3 (da) 2021-03-22
CA2986521A1 (en) 2011-05-19
SMT202100169T1 (it) 2021-07-12
HUE054000T2 (hu) 2021-08-30
PL2498610T5 (pl) 2024-11-04
ES2858337T3 (es) 2021-09-30
SI2498610T2 (sl) 2024-10-30
PH12012500939A1 (en) 2016-06-15
MX2012005560A (es) 2012-10-05
BR112012011427A2 (pt) 2015-10-06
SG10201407357PA (en) 2014-12-30
EA201290323A1 (ru) 2013-05-30
EP2498610B1 (en) 2018-03-14
EP3406142B1 (en) 2020-12-23
CN105061350B (zh) 2018-05-29
ES2673160T5 (es) 2024-11-19
KR20120102704A (ko) 2012-09-18
CN105061350A (zh) 2015-11-18
IL219691B (en) 2019-07-31
EP3406142A1 (en) 2018-11-28
EA024801B1 (ru) 2016-10-31
JP2013510885A (ja) 2013-03-28
NO2020039I1 (no) 2020-11-18
JP5650233B2 (ja) 2015-01-07
LTPA2020533I1 (lt) 2020-12-10
PH12015502708B1 (en) 2018-06-06
LT2498610T (lt) 2018-06-11
SI2498610T1 (en) 2018-07-31
CA2780772A1 (en) 2011-05-19
ES2673160T3 (es) 2018-06-20
CA2780772C (en) 2018-01-16
EP2498610B2 (en) 2024-06-19
CN102762100A (zh) 2012-10-31
HUE037535T2 (hu) 2018-09-28
US10239846B2 (en) 2019-03-26
CY1120338T1 (el) 2019-07-10
DK2498610T4 (da) 2024-09-09
SI3406142T1 (sl) 2021-08-31
BR112012011427B8 (pt) 2021-05-25
LT3406142T (lt) 2021-06-10
US20170320839A1 (en) 2017-11-09
PT2498610T (pt) 2018-06-19
US8362048B2 (en) 2013-01-29
EP3406142B8 (en) 2021-03-03
IL267956A (en) 2019-09-26
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
HRP20180874T4 (hr) Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze
HRP20201243T1 (hr) N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20161103T1 (hr) Kemijski spojevi
HRP20131027T1 (hr) Analozi 4-hidroksimaslaäśne kiseline
HRP20150982T1 (hr) Novi modulatori sfingozin fosfat receptora
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
HRP20221325T1 (hr) Pripravci i postupci transmukozne apsorpcije
HRP20201946T1 (hr) Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora
HRP20161669T1 (hr) Kinolini kao inhbitori kalijevih ionskih kanala
HRP20150592T4 (hr) Organoborni esterski spojevi i njihove farmaceutske kompozicije
JP2013510885A5 (enExample)
HRP20171518T1 (hr) Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja
ME02728B (me) Jedinjenja i njihova upotreba kao bace inhibitori
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
HRP20120785T1 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
HRP20180196T1 (hr) Diketoni i hidroksiketoni kao aktivatori puta signalizacije katenina
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
HRP20151397T1 (hr) DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
HRP20150167T4 (hr) Spojevi kao antagonisti bradikinina-b1
HRP20171587T1 (hr) Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
MX2013009709A (es) Derivados de heteroarilo como moduladores de nachr alfa 7.
HRP20180018T1 (hr) Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja